Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial.
- Stintzing, Sebastian Department of Hematology and Oncology, Klinikum Grosshadern and Comprehensive Cancer Center, University Hospital Grosshadern, LMU Munich, Munich, Germany;
- Wirapati, Pratyaksha Swiss Institute of Bioinformatics, Lausanne, Switzerland;
- Lenz, Heinz-Josef Division of Medical Oncology, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA;
- Neureiter, Daniel Institute of Pathology, Salzburg, Austria;
- Fischer von Weikersthal, Ludwig MVZ Amberg, Amberg, Germany;
- Decker, Thomas Onkologie Ravensburg, Ravensburg, Germany;
- Kiani, Alexander Klinikum Bayreuth, Bayreuth, Germany;
- Vehling-Kaiser, Ursula Practice for Medical Oncology, Landshut, Germany;
- Al-Batran, Salah-Eddin Krankenhaus Nordwest, University Cancer Center, Frankfurt, Germany;
- Heintges, Tobias Medical Department II, Städtisches Klinikum Neuss Lukaskrankenhaus GmbH, Neuss, Germany;
- Kahl, Christoph Department for Hematology, Klinikum Magdeburg, Magdeburg, Germany;
- Kullmann, Frank Kliniken Nordoberpfalz, Weiden, Germany;
- Moehler, Markus H. University Medical Center Mainz, Mainz, Germany;
- Scheithauer, Werner Medical University of Vienna, Vienna, Austria;
- Held, Swantje ClinAssess GmbH, Leverkusen, Germany;
- Modest, Dominik Paul Department of Hematology and Oncology, Klinikum Grosshadern, University of Munich, Munich, Germany;
- Jung, Andreas Department of Pathology, University of Munich, Munich, Germany;
- Kirchner, Thomas Department of Pathology, Ludwig-Maximilians University of Munich, Munich, Germany;
- Tejpar, Sabine University Hospital Leuven, KUL, Leuven, Belgium;
- Heinemann, Volker Comprehensive Cancer Center, Ludwig-Maximilian-University of Munich, Munich, Germany;
Published in:
- Journal of Clinical Oncology. - American Society of Clinical Oncology (ASCO). - 2017, vol. 35, no. 15_suppl, p. 3510-3510
English
3510 Background: FIRE-3 compared 1st -line therapy with FOLFIRI plus either cetuximab or bevacizumab in 592 KRAS exon 2 wt mCRC patients. CMS is grouping CRCs according to their gene-signature in 4 different types. Relevance of CMS for the treatment of mCRC remains unclear. Methods: Patients were grouped according to tumor CRC-CMSs. Using ALMAC’s Xcel tissue array, gene signatures of FIRE-3 tumor samples were analyzed. Survival was compared using Kaplan-Meier estimation and log-rank tests. Hazard ratios (HR) were estimated according to the Cox proportional hazard method. Results: CMS classification could be determined in 385 specimens available from the ITT population (n = 592). In this KRAS exon 2 wt population (n = 385), frequencies were: CMS1 (10.4%), CMS2 (36.6%), CMS3 (11.7%), CMS4 (29.1%), non-consensus (12.2%). In RAS wt (n = 315), frequencies were: CMS1 (11.1%), CMS2 (38.1%), CMS3 (9.5%), CMS4 (29.5%), non-consensus (11.7%). Independent of the treatment, CMS was a strong prognosticator for ORR (p = 0.023), PFS (p < 0.001) and OS (p < 0.001). For data on CMS and treatment efficacy in the RAS wt population see the following table. Conclusions: CMS classification is prognostic for mCRC. The survival benefit in RAS wt previously observed for FOLFIRI cetuximab vs. FOLFIRI bevacizumab is not significantly different across CMS groups, although there are trends when comparing OS HR between categories with CMS4 showing the best HR. [Table: see text]
- Language
-
- English
- Open access status
- green
- Identifiers
-
- DOI 10.1200/jco.2017.35.15_suppl.3510
- ISSN 0732-183X
- Persistent URL
- https://sonar.ch/global/documents/159605
Statistics
Document views: 24
File downloads:
- Full-text: 0